Skip to main content
. Author manuscript; available in PMC: 2022 Jul 17.
Published in final edited form as: J Cyst Fibros. 2021 Jul 17;20(4):618–624. doi: 10.1016/j.jcf.2021.06.014

Table 2.

Unadjusted and adjusted models of pulmonary exacerbations, ppFEV1, and BMI as a function of smoke exposure cessation (N=3,633)

Unadjusted1 Adjusted2
OR 95% CI p-value OR 95% CI p-value
Pulmonary exacerbations
  Cessation: Intercept 0.79 0.71 0.87 <0.001 0.83 0.75 0.91 <0.001
  Cessation: Slope 0.94 0.90 0.97 0.001 0.94 0.91 0.98 0.003
β β
ppFEV1
  Cessation: Intercept 0.73 0.37 1.08 <0.001 0.69 0.34 1.04 <0.001
  Cessation: Slope 0.38 0.15 0.62 0.001 0.39 0.16 0.61 0.001
BMI percentile
  Cessation: Intercept 1.00 0.53 1.46 <0.001 1.03 0.57 1.50 <0.001
  Cessation: Slope 0.41 0.09 0.73 0.013 0.42 0.10 0.74 0.009
1

Includes time for all three outcomes and a quadratic of time for ppFEV1 and BMI percentile.

2

Adjusted for age at entry, sex, race/ethnicity, household size, income, father's education, health insurance, genotype, newborn screening, CFTR modulator use, P.aeruginosa, and B. cepacia; includes the quadratic for time.

Note: Changes in the intercept and slope correspond to changes in the first year of cessation and each additional year of cessation, respectively.